glp receptor 1 agonists GLP-1 for individualized treatment of type 2 diabetes mellitus Targeting GLP-1, GIP & GCG

Clinical utility of dipeptidyl peptidase-4 inhibitors: A descriptive summary of current efficacy trials

The average age for menopause, when your periods stop permanently, is 52, according to the U.S

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

Distinct from prior reviews that predominantly focus on a single drug class or limited clinical indications, this article systematically contrasts the mechanistic pathways, therapeutic efficacy, and safety profiles of GLP-1RAs versus GLP-1/GIP dual receptor agonists

H., & Sharifi, A

GIP and GLP-1 exert their effects by binding to their specific receptors, the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), and increasing the level of intracellular cyclic adenosine monophosphate (cAMP), in pancreatic cells